ValuEngine lowered shares of Coherus Biosciences (NASDAQ:CHRS) from a sell rating to a strong sell rating in a research report report published on Friday.
Several other brokerages have also issued reports on CHRS. BidaskClub raised Coherus Biosciences from a hold rating to a buy rating in a research report on Saturday, January 13th. Zacks Investment Research lowered Coherus Biosciences from a hold rating to a sell rating in a research report on Tuesday, October 10th. Finally, Citigroup reaffirmed a buy rating and set a $23.00 target price on shares of Coherus Biosciences in a research report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $29.67.
Coherus Biosciences (NASDAQ CHRS) opened at $9.95 on Friday. The stock has a market capitalization of $595.41, a price-to-earnings ratio of -1.84 and a beta of 3.81. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 1.84. Coherus Biosciences has a 12-month low of $8.05 and a 12-month high of $27.45.
Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities research analysts anticipate that Coherus Biosciences will post -4.39 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the company. Legal & General Group Plc raised its position in shares of Coherus Biosciences by 12.6% in the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 1,046 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Coherus Biosciences in the 4th quarter worth about $135,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Coherus Biosciences by 497.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 10,491 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Coherus Biosciences in the 2nd quarter worth about $185,000. Finally, Fox Run Management L.L.C. bought a new position in shares of Coherus Biosciences in the 4th quarter worth about $228,000. 78.87% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/05/valuengine-lowers-coherus-biosciences-chrs-to-strong-sell.html.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.